Drugs / AND019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05187832 | Oct 2022 → Nov 2026 expected | Her2-receptor negative breast cancer | Kind Pharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AND019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05187832 ↗ |
| Route | Oral | “AND019 administrated as oral capsule once per day for 28 days for each cycle” NCT05187832 ↗ |